Predictors for major cardiovascular events—Cox regression analysis with age as time scale (n=1090, 85 events)
| Model 1* | Model 2† | Multivariate reduced‡ | ||||
|---|---|---|---|---|---|---|
| Variable | RR (95% CI) | p Value | RR (95% CI) | p Value | RR (95% CI) | p Value |
| Smoker: ever | 1.54 (0.93 to 2.56) | 0.09 | 1.60 (0.96 to 2.67) | 0.09 | ||
| Hypertension | 1.85 (1.18 to 2.90) | 0.007 | 1.81 (1.12 to 2.92) | 0.015 | ||
| Diabetes | 3.00 (1.79 to 5.02) | <0.0001 | 2.72 (1.60 to 4.62) | 0.0002 | ||
| High cholesterol | 1.39 (0.87 to 2.19) | 0.16 | ||||
| High triglyceride | 1.76 (1.10 to 2.81) | 0.02 | 1.42 (0.87 to 2.32) | 0.16 | ||
| Duration of psoriasis | 1.00 (0.99 to 1.02) | 0.60 | 1.00 (0.99 to 1.02) | 0.69 | ||
| Tender joint count | ||||||
| 1–7 vs 0 | 1.96 (1.17 to 3.26) | 0.01 | 1.94 (1.15 to 3.27) | 0.01 | ||
| >7 vs 0 | 2.14 (1.17 to 3.89) | 0.01 | 1.76 (0.95 to 3.26) | 0.07 | ||
| Swollen joint count | ||||||
| 1–7 vs 0 | 1.28 (0.79 to 2.06) | 0.31 | 1.17 (0.72 to 1.90) | 0.53 | ||
| >7 | 1.69 (0.89 to 3.20) | 0.11 | 1.48 (0.77 to 2.86) | 0.24 | ||
| Enthesitis count | 1.22 (0.94 to 1.61) | 0.14 | 1.25 (0.94 to 1.65) | 0.12 | ||
| Dactylitis count | 1.23 (1.11 to 1.36) | <0.0001 | 1.21 (1.10 to 1.35) | 0.0002 | 1.20 (1.08 to 1.34) | 0.0008 |
| Damaged joint count | ||||||
| 1–9 vs 0 | 1.44 (0.82 to 2.50) | 0.20 | 1.54 (0.86 to 2.75) | 0.14 | ||
| 10–19 vs 0 | 1.23 (0.60 to 2.52) | 0.57 | 1.26 (0.60 to 2.66) | 0.54 | ||
| ≥20 vs 0 | 1.30 (0.63 to 2.66) | 0.47 | 1.53 (0.74 to 3.17) | 0.25 | ||
| PASI | ||||||
| 10–19 vs <10 | 0.99 (0.39 to 2.47) | 0.98 | 0.83 (0.33 to 2.09) | 0.68 | ||
| >19 vs <10 | 0.92 (0.22 to 3.78) | 0.91 | 0.92 (0.22 to 3.81) | 0.91 | ||
| Urate (log µmol/L) | 1.67 (0.79 to 3.52) | 0.18 | 1.41 (0.69 to 2.88) | 0.34 | ||
| ESR | 0.008 | 0.01 | 0.02 | |||
| Men | 1.13 (0.87 to 1.47) | 1.09 (0.83 to 1.43) | 1.04 (0.79 to 1.37) | |||
| Women | 1.91 (1.19 to 3.07) | 1.87 (1.15 to 3.05) | 1.83 (1.12 to 2.99) | |||
| Leucocytes (log ×109/L) | 1.90 (1.00 to 3.61) | 0.049 | 1.73 (0.87 to 3.43) | 0.11 | ||
| Neutrophils (log ×109/L) | 1.75 (1.04 to 2.96) | 0.04 | 1.68 (0.92 to 3.06) | 0.09 | ||
| HAQ | ||||||
| 0.1–0.5 vs 0 | 1.28 (0.69 to 2.36) | 0.43 | 1.10 (0.57 to 2.11) | 0.77 | ||
| >0.5 vs 0 | 1.20 (0.61 to 2.38) | 0.59 | 0.90 (0.45 to 1.80) | 0.76 | ||
| SF-36 PCS | ||||||
| 31–45 vs <30 | 1.07 (0.65 to 1.76) | 0.78 | 1.13 (0.66 to 1.91) | 0.65 | ||
| >45 vs <30 | 0.43 (0.22 to 0.84) | 0.01 | 0.52 (0.26 to 1.03) | 0.06 | ||
| Medication use | ||||||
| Anti TNF vs none | 0.99 (0.48 to 2.01) | 0.98 | 0.99 (0.47 to 2.04) | 0.97 | ||
| MTX vs none | 1.64 (0.64 to 4.14) | 0.29 | 1.62 (0.62 to 4.21) | 0.33 | ||
| Other DMARDs vs none | 0.82 (0.45 to 1.50) | 0.52 | 0.96 (0.52 to 1.79) | 0.91 | ||
| Oral corticosteroids | 1.84 (0.67 to 5.09) | 0.23 | 1.58 (0.56 to 4.44) | 0.39 | ||
| Use of NSAIDs | 0.91 (0.58 to 1.41) | 0.67 | 0.91 (0.58 to 1.42) | 0.68 | ||
Bolded items are statistically significant in multivariate analysis.
*Each model included a single predictor, sex and PsA duration.
†Each model included the predictor on the respective row with sex, PsA duration, hypertension, diabetes, smoking and high triglyceride.
‡The full model included sex, PsA duration, diabetes, smoking and high triglyceride.
DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; RR, relative risk; TNF, tumour necrosis factor.